Is Alnylam publicly traded?
Is Alnylam publicly traded?
When did Alnylam go public? Alnylam started trading publicly in May 2004.
Is Alnylam profitable?
Alnylam Pharmaceuticals is bordering on breakeven, according to the 20 American Biotechs analysts. They expect the company to post a final loss in 2022, before turning a profit of US$30m in 2023. The company is therefore projected to breakeven around 2 years from today.
Who is Dr John Maraganore?
Dr. John Maraganore is a Senior Advisor at General Atlantic, providing strategic support and advice to the firm’s investment teams and portfolio companies in the Life Sciences sector. Since 2002, Dr. Maraganore has served as the CEO of Alnylam, a biopharmaceutical company focused on RNAi therapeutics.
Is Alnylam a good company?
Alnylam Pharmaceuticals is a great company to work for. It is consistently ranked as one of the top companies to work for in Boston. The company is located in Cambridge Massachusetts right by the Kendall/MIT stop.
Who bought Alnylam?
In 2014, Sanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company’s drugs for $700 million.
Why is Alnylam stock up?
The 22% rise can primarily be attributed to the recent announcement of positive data from a phase three study of Onpattro for patients with hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy progression after receiving an orthotopic liver transplant.
Where is Alnylam based?
Cambridge, Massachusetts
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Is Alnylam a rare disease company?
Alnylam Publishes Its 1st-Ever Rare Disease Trend Report | Alnylam® Newsroom.
When was Alnylam founded?
June 2002
Alnylam Pharmaceuticals/Founded
Who started Alnylam?
Paul Schimmel
Phillip Allen Sharp
Alnylam Pharmaceuticals/Founders
In 2002, Alnylam was founded by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore, and by investors Christoph Westphal and John Kennedy Clarke; John Maraganore was the founding CEO. The company was named after Alnilam, a star in Orion’s belt.
Who owns Givlaari?
Alnylam Is the Leading RNAi Therapeutics Company Our second medicine, GIVLAARI® (givosiran), was approved in 2019, followed closely by our third medicine, OXLUMO® (lumasiran), which was approved by the FDA in 2020.
https://www.youtube.com/watch?v=WNSq74_DlCg